Yang Lab

Despite decades of efforts, cancer metastasis remains largely incurable and causes about nine million deaths worldwide annually. Preventing or delaying metastasis holds tremendous potential for substantially prolonging the survival time and improving the quality of life of cancer patients. Nevertheless, there is a paucity of clinically actionable targets for inhibiting cancer metastasis as well as biomarkers for selecting appropriate patients and monitoring drug response. The Yang Laboratory focuses on addressing these pressing clinical needs.

Because proteins are the major functional molecules in cells and preferred targets for therapeutic agents and diagnostic tests, we develop multilevel proteomics methods and bioinformatic algorithms to comprehensively analyze protein abundance, post-translational modification and interaction. Coupling with in-depth phenotypic and mechanistic studies, we apply these leading-edge proteomics approaches to identify and credential high-value, clinically actionable targets and biomarkers. We also collaborate with physicians and oncologists to translate discoveries from bench to bedside to benefit cancer patients.

The Yang Laboratory is affiliated with the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, Department of Surgery and Department of Biomedical Sciences.